Deepa Jeyakumar, MD, from UC Irvine Health discusses how IDH2 inhibitor for AML is effective with Relapsed Refractory disease and the differentiation syndrome is a worrying side-effect all at MOASCs Spotlight On® Hematology in Huntington Beach.
IDH2 Inhibitor for AML is Effective with RR Disease – Differentiation syndrome is a worrying side-effect
